352,087 Shares in enGene Holdings Inc. $ENGN Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. acquired a new position in enGene Holdings Inc. (NASDAQ:ENGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 352,087 shares of the company’s stock, valued at approximately $3,179,000. enGene accounts for approximately 0.6% of Privium Fund Management B.V.’s investment portfolio, making the stock its 26th biggest position.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Braidwell LP acquired a new stake in enGene in the third quarter worth about $15,479,000. Citadel Advisors LLC boosted its holdings in enGene by 153.3% during the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock worth $399,000 after buying an additional 35,327 shares during the last quarter. Millennium Management LLC boosted its holdings in enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in enGene during the third quarter worth about $76,000. Finally, PFS Partners LLC boosted its holdings in enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after buying an additional 2,000 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Trading Up 3.7%

NASDAQ:ENGN opened at $7.89 on Wednesday. enGene Holdings Inc. has a fifty-two week low of $2.65 and a fifty-two week high of $12.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 11.75. The stock has a market capitalization of $528.55 million, a PE ratio of -3.51 and a beta of -0.02. The business’s 50-day simple moving average is $7.78 and its 200-day simple moving average is $8.36.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.11. Sell-side analysts expect that enGene Holdings Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ENGN. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a report on Wednesday, April 8th. Wall Street Zen cut enGene from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Raymond James Financial restated a “strong-buy” rating and set a $27.00 target price on shares of enGene in a report on Monday, March 9th. Guggenheim restated a “buy” rating on shares of enGene in a report on Tuesday, March 10th. Finally, Jefferies Financial Group began coverage on enGene in a report on Friday, January 30th. They set a “buy” rating and a $28.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, enGene currently has an average rating of “Moderate Buy” and an average price target of $22.69.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.